These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34418822)

  • 1. Comparative genomics of Enterobacter cloacae complex before and after acquired clinical resistance to Ceftazidime-Avibactam.
    Senchyna F; Tamburini FB; Murugesan K; Watz N; Bhatt AS; Banaei N
    Diagn Microbiol Infect Dis; 2021 Dec; 101(4):115511. PubMed ID: 34418822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo activity of ceftazidime/avibactam and aztreonam alone or in combination against mcr-9, serine- and metallo-β-lactamases-co-producing carbapenem-resistant Enterobacter cloacae complex.
    Li W; Zhang J; Fu Y; Wang J; Liu L; Long W; Yu K; Li X; Wei C; Liang X; Wang J; Li C; Zhang X
    Eur J Clin Microbiol Infect Dis; 2024 Jul; 43(7):1309-1318. PubMed ID: 38700663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of Resistance in Clinical Isolates of
    Liu L; Yu J; Tang M; Liu J
    Ann Clin Lab Sci; 2018 May; 48(3):355-362. PubMed ID: 29970440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
    Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
    Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H
    Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.
    Stone GG; Bradford PA; Yates K; Newell P
    J Antimicrob Chemother; 2017 May; 72(5):1396-1399. PubMed ID: 28088768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae.
    Livermore DM; Mushtaq S; Doumith M; Jamrozy D; Nichols WW; Woodford N
    J Antimicrob Chemother; 2018 Dec; 73(12):3336-3345. PubMed ID: 30247546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae.
    Venditti C; Butera O; Meledandri M; Balice MP; Cocciolillo GC; Fontana C; D'Arezzo S; De Giuli C; Antonini M; Capone A; Messina F; Nisii C; Di Caro A
    Clin Microbiol Infect; 2021 Jul; 27(7):1040.e1-1040.e6. PubMed ID: 33775814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.
    Stone GG; Newell P; Gasink LB; Broadhurst H; Wardman A; Yates K; Chen Z; Song J; Chow JW
    J Antimicrob Chemother; 2018 Sep; 73(9):2519-2523. PubMed ID: 29912399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analyses of a Ceftazidime-Avibactam-Resistant
    Castanheira M; Arends SJR; Davis AP; Woosley LN; Bhalodi AA; MacVane SH
    mSphere; 2018 Sep; 3(5):. PubMed ID: 30258039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014).
    Sader HS; Castanheira M; Jones RN; Flamm RK
    Diagn Microbiol Infect Dis; 2017 Mar; 87(3):261-265. PubMed ID: 28069328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal analysis of the in vitro activity of ceftazidime/avibactam versus Enterobacteriaceae, 2012-2016.
    Ramalheira E; Stone GG
    J Glob Antimicrob Resist; 2019 Dec; 19():106-115. PubMed ID: 31295583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Selection of Enterobacter cloacae with Cefepime, Meropenem, and Ceftazidime-Avibactam Generates Diverse Resistance Mechanisms.
    Castanheira M; Lindley J; Doyle TB; Davis AP; Sader HS
    Int J Antimicrob Agents; 2023 Jan; 61(1):106698. PubMed ID: 36464152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in Enterobacter cloacae Complex Following Exposure to Cefepime.
    Shields RK; Iovleva A; Kline EG; Kawai A; McElheny CL; Doi Y
    Clin Infect Dis; 2020 Dec; 71(10):2713-2716. PubMed ID: 32236408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
    Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.
    MacGowan A; Tomaselli S; Noel A; Bowker K
    J Antimicrob Chemother; 2017 Mar; 72(3):762-769. PubMed ID: 28039276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-to-Patient Transmission of Klebsiella pneumoniae Carbapenemase Variants with Reduced Ceftazidime-Avibactam Susceptibility.
    Munoz-Price LS; Reeme AE; Buchan BW; Mettus RT; Mustapha MM; Van Tyne D; Shields RK; Doi Y
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SHV-12 extended spectrum beta-lactamase associated with high-level ceftazidime resistance in Enterobacter cloacae isolated from Thailand.
    Tansawai U; Boonkerd N; Polwichai P; Dejsirilert S; Niumsup PR
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):148-54. PubMed ID: 19323047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
    Ackley R; Roshdy D; Meredith J; Minor S; Anderson WE; Capraro GA; Polk C
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates.
    MacVane SH; Crandon JL; Nichols WW; Nicolau DP
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6913-9. PubMed ID: 25223999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.